This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Immutep Class Action Lawsuits
Business class action lawsuit

Immutep Class Action Lawsuits

Analysis based on 85 articles · First reported Apr 07, 2026 · Last updated Jun 03, 2026

Sentiment
-70
Attention
4
Articles
85
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuits against Immutep by Pomerantz LLP and Rosen Law Firm are likely to further depress Immutep's stock price due to increased legal and financial uncertainty. Investors who purchased Immutep ADRs during the specified Class Period may be entitled to compensation, potentially leading to significant financial liabilities for Immutep.

biotechnology legal services
Event Summary

Immutep, a publicly traded biotechnology company, faced a significant stock price drop of 82.44% on March 13, 2026, after its Independent Data Monitoring Committee recommended the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa due to futility. This news led to multiple class action lawsuits filed by law firms, including Pomerantz LLP and Rosen Law Firm, alleging securities fraud and other unlawful business practices against Immutep and its officers/directors. These lawsuits seek compensation for investors who acquired Immutep securities during the Class Period, generally between March 24, 2025, and March 12, 2026, with a lead plaintiff deadline of July 6, 2026.

Entities Involved
stock
Immutep
Immutep's stock price fell significantly after the discontinuation of its TACTI-004 Phase III study, leading to multiple class action lawsuits alleging securities fraud.
Importance 100.0 Sentiment -90.0
priv
Pomerantz LLP
Importance 0.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
per
Danielle Peyton
Importance 0.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
Importance 0.0 Sentiment 0.0
Relationships
Immutep related ↔ Rosen Law Firm
Immutep related ↔ Philip Kim
Immutep related ↔ Lawrence Rosen
Pomerantz LLP competitor ↔ Rosen Law Firm Pomerantz LLP is a direct competitor to Rosen Law Firm, with both firms frequently vying to represent shareholders as le
Pomerantz LLP related ↔ Philip Kim
Pomerantz LLP related ↔ Lawrence Rosen
Pomerantz LLP related ↔ Danielle Peyton
Pomerantz LLP related ↔ United States — United States Securities and Exchange Commission
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Danielle Peyton
Rosen Law Firm none ↔ United States — United States Securities and Exchange Commission Rosen Law Firm has no direct structural or regulatory relationship with the SEC. The firm's connection to the agency is
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
Philip Kim competitor ↔ Danielle Peyton Philip Kim, a partner at Rosen Law Firm, regularly competes for lead counsel status in securities class actions against
Philip Kim unaffiliated ↔ United States — United States Securities and Exchange Commission Philip Kim is a private attorney whose securities class action lawsuits cite SEC regulations, but he holds no direct rel
+ 3 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.